
Terumo Corporation
TRUMY | OTC
$15.14
+$0.14 (+0.93%)
At close: Oct 30, 2026, 3:57 PM ET
$15.14
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 4:00 PM ET
Company Profile
Terumo Corporation is a global medical technology company dedicated to the manufacturing and sale of a wide array of medical products and equipment, operating through three distinct business segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular division provides critical devices for cardiovascular and cerebrovascular interventions, including angiographic guidewires, various catheters (angiographic, PTCA balloon, imaging), introducer sheaths, vascular closure devices, coronary and self-expanding peripheral stents, and intravascular ultrasound systems; it also develops specialized tools for cerebral aneurysm treatment like coils, stents, and intrasaccular devices, as well as embolization systems, aspiration catheters, and clot retrievers for ischemic stroke, further supplying oxygenators, cardio-pulmonary bypass systems, and artificial vascular and stent grafts. The Medical Care Solutions segment offers a comprehensive range of general medical products such as syringes, infusion and syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritional products, and adhesion barriers; for patient self-care, it provides blood glucose monitoring systems, disposable needles for pen-injectors, insulin patch pumps, blood pressure monitors, and digital thermometers, while also performing contract manufacturing for pharmaceutical companies, producing prefillable syringes and needles for drug packaging. The Blood and Cell Technologies division focuses on innovations in blood and cell management, offering products such as blood bags, component collection systems, automated blood processing and pathogen reduction systems, centrifugal apheresis systems, and cell expansion systems. Originally founded in 1921 as Sekisen Ken-onki Corporation, the company adopted the name Terumo Corporation in October 1974 and maintains its headquarters in Tokyo, Japan.
Key Executives
| Name | Position |
|---|---|
| Hikaru Samejima | Representative Director, President & Chief Executive Officer |
| Jin Hagimoto | Chief Financial Officer, Chief Information Officer, GM of Accounting, Corporate Planning, Tax, IT Planning Dept. & GBS |
| Miho Mizuguchi | Executive Officer, Chief Legal Officer and GM of CLO Office, Legal & Compliance Department |
| Shinji Omori | Chief Technology Officer, Corporate R&D Officer, GM of R&D Center & Executive Officer |
| Fumihisa Hirose | Group Managing Executive Officer |
| Itaru Sakaguchi | Group Managing Executive Officer |
| Kenichi Hata | Executive Officers & Head of Corporate Planning Office |
| Norimasa Kunimoto | Director & Group Managing Executive Officer |
| Tomoko Adachi | Chief Human Resources Officer & Group Executive Officer |
| Toshihiko Osada | Group Senior Managing Executive Officer & Director |
Terumo Corporation

| Country | Japan |
| IPO Date | Jan 5, 2010 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 30,207 |
| CEO | Hikaru Samejima |
Stock Details
| Ticker Symbol | TRUMY |
| Exchange | OTC |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 88156J105 |
| ISIN Number | US88156J1051 |
| SIC Code | n/a |
Recent News
- 14 days ago / seekingalpha.comTerumo Corporation (TRUMY) Discusses Technological Capabilities and R&D Strategy for Sustained Competitive Advantage Transcript
- 19 days ago / zacks.comTerumo (TRUMY) Upgraded to Strong Buy: What Does It Mean for the Stock?
- 3 months ago / seekingalpha.comTerumo Corporation (TRUMY) Q1 2027 Earnings Call Prepared Remarks Transcript
- 3 months ago / zacks.com4 Medical Products Stocks Poised to Win Despite Industry Headwinds
- 1 year ago / globenewswire.comOrchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
Add to Watchlist
Select watchlists to add or remove TRUMY